Daniel Schuppmann, LL.M.
Senior Associate
- Intellectual Property
- Life Sciences, Healthcare & Clinical Trials
- Commercial Agreements
- Technology & Data Protection
As a Senior Associate at NEUWERK, Daniel advises national and international clients on IP, technology and data protection law as well as commercial agreements. A key focus of his practice is the drafting and negotiation of strategic collaborations, research and development agreements, licensing arrangements and software, outsourcing and technology agreements. He also advises on M&A transactions, carve-outs and strategic projects involving intellectual property, technology and data.
Handelsblatt and Best Lawyers recognized Daniel as a “One to Watch – Lawyer of the Future” in 2024, 2025 and 2026. In 2026, he was recommended in the areas of intellectual property, information technology law, biotechnology and life sciences, and data protection law.
Daniel's clients include multinational corporations, investors, fast-growing start-ups and spin-outs as well as academic institutions, hospital groups and research organizations.
His practice spans a broad range of industries, with a particular focus on life sciences, pharma, biotech and medtech. Daniel advises companies and research institutions throughout the entire development and commercialization lifecycle, from early-stage research and development, licensing and collaboration projects, clinical trials and regulatory approval to manufacturing, supply, distribution and commercialization. In this context, he has particular experience advising on site and CRO agreements, data protection matters involving health data and collaborations between sponsors, hospitals, investigators and research partners.
CV
Daniel studied law at Bucerius Law School in Hamburg and at Singapore Management University in Singapore. He also completed the LL.M. program "International Technology Law" at the Vrije Universiteit in Amsterdam, with a focus on legal issues relating to the use of artificial intelligence in the medical sector.
Daniel completed his legal clerkship at the Hanseatic Higher Regional Court in Hamburg, during which he worked for Hogan Lovells in the practice group "IP, Media & Technology" as well as at a chamber at the Regional Court of Hamburg specialized in intellectual property law. He further worked for the South Korean law firm Kim & Chang in Seoul and NEUWERK in his current areas of practice.
Recent work
Life sciences
One of Germany's leading private hospital groups in ongoing advice on clinical trials, research collaborations, consortium agreements as well as data protection and regulatory issues relating to the handling of health data
University Hospital Cologne on a licence and collaboration agreement with BioNTech to research novel approaches against HIV
Ongoing advice to a leading German research-based pharmaceutical company on R&D, licensing, contract manufacturing and procurement, in particular high-volume supply agreements, collaboration agreements and clinical trials in pain and adjacent indications
A Berlin-based biotechnology company on a licensing and distribution collaboration with a US pharmaceutical company in the field of severe bacterial infections, plus ongoing advice on all licensing and distribution collaborations
German Center for Infection Research (DZIF), a nationwide research alliance with more than 500 scientists across 35 institutions, on a large-scale collaboration and licence option agreement with AiCuris Anti-Infective Cures to identify new antiviral targets and innovative R&D approaches for treatment and prophylaxis in immunocompromised patients
Ongoing advice to a German biotech developing targeted cancer therapies on all R&D and licensing matters, including research and collaboration agreements, IP licence agreements, option arrangements, MTAs and NDAs
A German pharmaceutical company focused on antiviral small-molecule therapeutics on clinical trial advice, site agreements, CRO agreements, clinical research structures and data protection issues relating to the handling of health data
A leading European protein engineering company on multiple commercial and IP-related agreements, including global R&D collaborations and licence agreements
An Australian pharmaceutical manufacturer on a cross-border commercial supply agreement including validation, development, regulatory support, stability matters, IP issues and divestiture-related questions
M&A, carve-outs & outsourcing
Family Trust on the acquisition of AIS Aßmann Industrie Steckverbinder GmbH and ISK GmbH Industriesteckverbinder Zubehör & Kabelkonstruktion (IP/IT and commercial)
Altamount Software Group, a subsidiary of CHAPTERS Group AG, on the acquisition of Somentec Software GmbH, a leading billing software provider for the energy sector (focus on IP and software)
Warburg Pincus on the acquisition of a majority stake in Uvex, a global leader in personal protective equipment (IP/IT and data protection)
KPS Capital Partners on the acquisition of Sport Group, a global leader in artificial turf systems and synthetic sports and leisure surfaces with more than EUR 500 million in annual revenue (IP/IT and data protection)
Carlyle on the public takeover offer of about EUR 450 million for SNP Schneider-Neureither, a listed German IT company specialising in SAP data management, at EUR 61 per share (IP/IT and data protection)
A leading European pharmaceutical company on manufacturing and distribution matters in connection with a carve-out and the acquisition of a broad product portfolio from a global pharma company
Outsourcing advice to Fresenius SE and Fresenius Digital Technology on the large-scale migration of core IT systems to Capgemini covering approximately 1,000 sites in more than 80 countries
Arcadea on the acquisition of the Brandenburg-based IT company Zedas, which provides software solutions for logistics management in long-haul and shunting operations as well as fleet and infrastructure management (IP/IT and data protection)
The management team of Berlin-based creative agency RCKT. on the sale to Dentsu (IP/IT and data protection)
Tradedoubler on the acquisition of Zezam (KAHA GmbH), a German creator-commerce platform, for integration into its influencer business Metapic (IP/IT and data protection)
Technology, data and commercial contracting
A Hamburg-based leading developer of advanced real-time 3D graphics software, used for example at the Olympic Games and the Super Bowl, on ongoing advice across IT contracts
Fast-growing mid-cap industrial company in the sanitary sector with sites in Germany, Poland, Italy and France on the design of cross-border supply and distribution agreements
A provider of a KYC/KYB compliance platform on SaaS agreements, data protection matters and the contractual structuring of digital compliance solutions
Leading manufacturer of magnetic alloys and value-added product solutions on terms and conditions and supply agreements
A Hamburg eHealth specialist for patient-monitoring services in ICUs on all contracts for building central IT systems and on outsourcing and service collaborations with several hospital groups
An international chemicals group on a complete data-protection re-baseline following a carve-out
A digital health start-up on all legal matters, in particular clinical trials, compliance of digital health applications (DiGA), data protection, terms of use, distribution and collaboration agreements
German mid-cap industrial company with international operations on T&Cs compliance, warranty regimes and supply agreements and terms for drive solutions in automation
Publications
Die neuen Standardvertragsklauseln für die Durchführung klinischer Prüfungen – Darstellung und praktische Einordung, PharmR 2026, 289 (together with Dr. Malin Fischer)
Datenschutz in klinischen Prüfungen/Studien aus juristischer Sicht, Presentation at the annual meeting of the German Quality Management Association e.V., March 2024
From Lab to Launch: Navigating the Legal Labyrinth of Life Science Startups - How to Transfer Intellectual Property from Academia to the Market and Navigate the Nuances of Founding a Company in Germany, Presentation at the Life Science Start-up Day 2024 (organized by: BioRegioN, Life Science Factory, Ottobock, Sartorius and startup.niedersachsen)
Regulierung von KI durch EU-Gesetzgebung. Was erwartet die Life-Sciences-Industrie durch die geplante KI-Verordnung?, Plattform Life Sciences, 3/2022
Rechtliche Fragen der Kommerzialisierung von KI-Systemen, Plattform Life Sciences, 2/2021
Languages
German
English
P +49 40 340 57 57 - 63 F +49 40 340 57 57 - 55 M +49 170 96 42 697